Lifetech CeraFlex™ ASD Closure System Post-Market Clinical Follow-Up
ConditionAtrial Septal Defect
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorLifetech Scientific (Shenzhen) Co., Ltd.
About this trial
The objective of this post-market registry is to assess the clinical use of the Lifetech CeraFlex™ Closure System in a real-world and on-label fashion.
Eligibility criteria
Qualifiers
Patients with a confirmed diagnosis of Atrial Septal Defect (ASD) and implanted with the investigational device as per IFU instructions.
Patients or legally authorized representatives have signed Data Release Consent or equivalent documents.
Disqualifiers
None
Trial design
Treatments tested in this trial
- CeraFlex™ Atrial Septal Defect (ASD) Closure System
Treatment groups
145 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov